Welcome to our dedicated page for Sihuan Pharma news (Ticker: SHPHY), a resource for investors and traders seeking the latest updates and insights on Sihuan Pharma stock.
SIHUAN PHARM HLDGS reports pharmaceutical developments tied to its operating subsidiaries and China drug approvals. Company news centers on Xuanzhu Biopharm, including NMPA marketing approval for Xuanyuening® (bireociclib tablets), a CDK4/6 inhibitor for HR+/HER2- advanced or metastatic breast cancer, and Anaprozole Sodium Enteric-coated Tablets, a proton pump inhibitor approved for duodenal ulcer.
Updates also cover subsidiary-level financing and commercialization activity, including Huisheng Biopharmaceutical's diabetes and complications product pipeline. The company's recurring news themes include innovative-drug approvals, therapeutic indications, clinical and commercialization progress, and capital actions within its biopharmaceutical subsidiaries.
Summary not available.
Summary not available.
Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, completed an A+ round of financing, raising RMB580 million (approximately HK$650 million). This capital increase enhances Huisheng's registered capital to RMB372 million and values the company at RMB5.58 billion. The funds will be directed towards marketing and clinical advancements in diabetes treatment. Sihuan's share in Huisheng stands at approximately 61.29%, signaling investor confidence in its R&D capabilities and future prospects.